Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free
Nymox Pharmaceutical NASDAQ NYMX
$0.47 -0.06 -13.34%
Today share price
Bahamas
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 11 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

42.68M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
41.45M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.53
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
91.27M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-
Upcoming events Nymox Pharmaceutical All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Nymox Pharmaceutical

Stock analysis Nymox Pharmaceutical

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-3.69 14.93
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
-88.54 3.72
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
41.04 9.72
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
-1.22 -0.17
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
402.50 11.19

Price change Nymox Pharmaceutical per year

1.25$ 3.50$
Min Max

Summary analysis Nymox Pharmaceutical

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Nymox Pharmaceutical

Revenue and net income Nymox Pharmaceutical

All parameters
Stock news Nymox Pharmaceutical All news
6 July 2023 в 01:40

Nymox Pharmaceutical to Be Suspended From Nasdaq, Move to OTC

6 July 2023 в 01:40

Nymox Pharmaceutical to Be Suspended From Nasdaq, Move to OTC

24 May 2022 в 01:36

Nymox Pharmaceutical Down 64% on FDA Refusal to File Letter

24 May 2022 в 01:36

Nymox Pharmaceutical Down 64% on FDA Refusal to File Letter

About company Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.
Address:
Bay & Deveaux Streets, Nassau, Bahamas
Company name: Nymox Pharmaceutical
Issuer ticker: NYMX
ISIN: BSP733981026
Country: Bahamas
Exchange: NASDAQ
Currency: $
IPO date: 1997-12-01
Sector: Healthcare
Industry: Biotechnology
Site: https://www.nymox.com

On which stock exchange are Nymox Pharmaceutical (NYMX) stocks traded?

Nymox Pharmaceutical (NYMX) stocks are traded on NASDAQ.

What is the ticker of Nymox Pharmaceutical stocks (NYMX)?

The stock ticker of Nymox Pharmaceutical’s stocks or in other words, the code is NYMX. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Nymox Pharmaceutical (NYMX) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Nymox Pharmaceutical (NYMX) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Nymox Pharmaceutical (NYMX) stocks traded?

Nymox Pharmaceutical (NYMX) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Nymox Pharmaceutical (NYMX) stocks today?

The current price of Nymox Pharmaceutical stocks on 18.04.2024 is 0.4676 dollars. per share.

What is the dynamics of Nymox Pharmaceutical (NYMX) stocks from the beginning of the year?

Nymox Pharmaceutical (NYMX) quotes have increased by 0% from the beginning of the year up to 0.4676 dollars. per 1 stocks.

How much did Nymox Pharmaceutical (NYMX) stocks increase in апреле 2024?

This month Nymox Pharmaceutical (NYMX) quotes have increased by 0% to 0.4676 dollars. per share.

How much are Nymox Pharmaceutical (NYMX) stocks worth?

Today, on October, 18.04.2024 Nymox Pharmaceutical’s (NYMX) stocks cost 0.4676 dollars..

What is the market capitalization of Nymox Pharmaceutical (NYMX)?

Capitalization is the market value of Nymox Pharmaceutical (NYMX) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 18.04.2024, the market capitalization of Nymox Pharmaceutical (NYMX) is estimated at about 42675579 dollars.